drugset / Trial / NCT03492125
A Study Of The Selective PKC-β Inhibitor MS- 553
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Timeline
- Start
- 2018-05-25
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Outcome
Outcome not reported
Stopped: “The study is terminated due to major protocol revisions. A new study in CLL patients is planned.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Subject | MS-553 | Unknown | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Venetoclax | Small molecule | — | Oral |